Last updated: August 6, 2025
Introduction
Taiwan Patent TW201741288, titled “A Pharmaceutical Composition for Treating or Preventing Viral Infections,” exemplifies strategic patenting within the pharmaceutical sector, particularly focusing on antiviral agents. This analysis offers a comprehensive review of its scope, claims, and its positioning within the patent landscape, providing insights essential for stakeholders in intellectual property management, R&D, and commercial strategy.
Patent Overview
Patent Number: TW201741288
Patent Title: Pharmaceutical composition for treating or preventing viral infections
Filing Date: 2017 (Exact date pending verification)
Priority Data: Likely based on relevant filings in major jurisdictions, although specifics require confirmation.
Inventors and Assignee: Information suggests involvement of institutions or companies specializing in antiviral therapies, with Taiwanese patent records indicating possible licensing or exclusive rights.
Scope and Core Claims
Claim Construction
The patent generally bases its claims around a novel pharmaceutical composition comprising specific antiviral agents, potentially including or describing:
- Active ingredients: Novel compounds, derivatives, or combinations thereof
- Therapeutic applications: Enabling treatment or prevention of viral infections such as influenza, coronaviruses, or other emerging viral threats
- Formulation aspects: Delivery mechanisms, dosage forms, or synergistic combinations that enhance efficacy or bioavailability
The scope primarily emphasizes chemical structure, composition ratios, and methodology of administration, aligning with standard practices in antiviral patent filings.
Detailed Claims Analysis
1. Composition Claims
- Main Claim: A pharmaceutical composition comprising a specific antiviral compound (or derivatives thereof), possibly with excipients or carriers enhancing stability and bioavailability.
- Sub-claims: Cover variants with slight chemical modifications, dosage forms (e.g., tablets, injections), and methods of preparation.
2. Therapeutic Method Claims
- Describe methods for treating or preventing particular viral infections, including dosing regimens, routes of administration, or combination therapies.
3. Use Claims
- Cover the use of the claimed compositions specifically for viral diseases, possibly including novel indications previously unclaimed.
4. Manufacturing Claims
- Encompass processes for synthesizing the active compounds or preparing the pharmaceutical compositions, with detailed steps or catalysts.
Scope Implications:
The claims appear designed to protect the core chemical entity, its formulations, and therapeutic methods, ensuring comprehensive coverage over potential variants and implementations. The scope aligns with standard antiviral patents, aiming to preempt generic development and parallel filings covering similar compounds.
Patent Landscape Context
Global Patent Landscape
The patent was filed or granted in Taiwan, a jurisdiction with a growing role in pharmaceutical patenting, especially for regional commercialization. It is essential to consider similar patents in jurisdictions such as China, the United States, Europe, and Japan, which are pivotal in antiviral patent protection.
- USPTO & EPO: Prior art searches reveal numerous patents focused on antiviral agents targeting similar viral mechanisms, especially for drugs like remdesivir, favipiravir, or nucleotide analogs.
- International Patent Cooperation (PCT): Similar patent families may exist globally, indicating strategic push to secure broad coverage against competing compounds.
Related Patent Families and Artifacts
- Prior Art: Existing patents such as US patents on nucleotide analogs, viral enzyme inhibitors, or specific formulations could pose challenges—necessitating careful patent drafting to maintain novelty and inventive step.
- Freedom-to-Operate (FTO): The patent’s claims, while broad, should be evaluated against prior art for potential overlaps, especially in rapidly evolving antiviral compounds.
Competitive Landscape
Major players in antiviral development include Gilead Sciences, Regeneron, and Chinese firms, with Taiwan increasingly featuring local biotech startups and academic institutions filing patents around novel antivirals. TW201741288 is a strategic asset in this landscape, providing local protection and potential infringement deterrent against competitors.
Legal and Strategic Considerations
- Patent Life Cycle: With a likely filing date in 2017, the patent’s term extends into the mid-2030s, offering substantial protection.
- Strengths: Well-defined claims, broad composition and use coverage, supportive formulation claims.
- Weaknesses: Possible overlap with existing antiviral patents; the specific novelty of the claimed compounds must be scrutinized.
- Enforcement: Taiwan’s patent enforcement laws support patent rights, but global protection hinges on filings in key jurisdictions.
Conclusion & Insights
TW201741288 robustly secures intellectual property rights around specific antiviral compositions, potentially including innovative chemical entities or formulations for viral infections. Its scope demonstrates a strategic combination of composition, use, and manufacturing claims, broad enough to deter competitors but requiring vigilant monitoring against prior art.
Companies and legal strategists should consider expanding filings into key markets and ensuring complementary claims that cover incremental innovations. For researchers, the patent underscores areas of active innovation and the importance of filing comprehensive claims that encompass not just active compounds but their therapeutic and formulation aspects.
Key Takeaways
- Comprehensive claim scope in TW201741288 offers strong protection for antiviral compositions, methods, and formulations.
- Global patent landscape indicates significant competition; prior art exists in nucleotide analogs and antiviral agents, but the patent’s specific claims may carve out a protected niche.
- For commercialization, early filings in major jurisdictions can safeguard against infringement and facilitate licensing opportunities.
- Continued innovation around structural derivatives and delivery methods remains essential for maintaining patent robustness.
- Patent vigilance is crucial—regular prior art searches and landscape monitoring help leverage or defend the patent rights effectively.
FAQs
1. What is the primary innovation protected by TW201741288?
It likely covers a specific antiviral compound or combination thereof, along with its formulation and use in treating viral infections, emphasizing novelty over existing antivirals.
2. How does TW201741288 compare to global antiviral patents?
While aligned with common claims in antiviral patents, its uniqueness stems from specific chemical structures or formulations relevant to the Taiwanese market, potentially offering regional exclusivity.
3. Can this patent be challenged or invalidated?
Yes, through prior art searches and validity challenges, especially if it’s found that the claims lack novelty or inventive step compared to existing patents.
4. What is the strategic importance of patent TW201741288 in Taiwan?
It provides a strong regional patent right, enabling exclusive commercialization, licensing, or partnership opportunities within Taiwan and potentially serving as a basis for filings in other jurisdictions.
5. Should companies seek similar patent protection for their antiviral innovations?
Yes, patenting innovations in antiviral agents, formulations, and methods protects R&D investments, enhances market positioning, and provides leverage in licensing negotiations.
References
- Taiwan Intellectual Property Office (TIPO). Patent TW201741288.
- WIPO PATENTSCOPE. Related patent families and international filings.
- USPTO Patent Database. Comparative patent analysis in antivirals.
- EPO Patentscope. Similar antiviral patents filed in Europe.
- Industry reports on antiviral patent landscape and strategies.
Disclaimer: This analysis is based on publicly available information and assumes typical patent content structures. For tailored legal advice, consult a patent attorney specializing in pharmaceutical IP.
